I-China 200124-22-7 Tert-butoxycarbonyl-arginine(Pbf)-OH Umkhiqizi kanye Nemboni |Jiayinglai

200124-22-7 Tert-butoxycarbonyl-arginine(Pbf)-OH

Incazelo emfushane:

Ukubukeka	Amakristalu amhlophe kuya kokumhlophe noma impushana ecwebezelayo.
MF	I-C24H38N4O7S
MW	526.65
Ubumsulwa	98+

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Isimo sezokuthutha&indlela yokuthumela enconyiwe:
ngomoya, ngolwandle noma nge-express

Isimo sesitoreji:
Ivalwe endaweni eyomile, Gcina efrijini, ngaphansi kuka -20°C

Ubuncane be-oda Ubuningi:
Ukuxoxisana

Isitifiketi:
I-COA, HPLC, GC, HNMR, Assay, Water Content(KF), TLC iyatholakala

Omqondofana

I-N5--[[(2,3-Dihydro-2,2,4,6,7-pentamethylbenzofuran-5-yl)sulfonyl]amino]iminomethyl]-N2-BOC-L-ornithine;
I-Nα-Boc-Nω-(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sufonyl) -L-arginine;
I-Nalpha-Boc-Nomega-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzo[b]furan-5-sulfonyl) -L-arginine;
I-BOC-ARGININE(PBF)-OH;BOC-L-ARG(PBF)-OH;
I-BOC-N-OMEGA-(2,2,4,6,7-PENTAMETHYLDIHYDROBENZOFURAN-5-SULFONYL)-L-ARGININE

Ukupakisha kwangaphakathi

Ngokuvamile zisetshenziselwa ukupakisha impushana.Futhi zingavimbela ukukhanya kwelanga namanzi ukuba kungabi kubi.

ukupakisha kwangaphandle

Ibhokisi eliqinile lingavikela imikhiqizo yakho ukuthi ingaphahlazeka futhi ibe manzi.

Izinhlelo zokusebenza

I-Boc-Arg (Pbf) -OH iphuma e-arginine.
I-Bivalirudine, i-anticoagulant yokwenziwa engu-20-peptide umzala we-hirudin, yagunyazwa ukudayiswa e-United States ngo-2000. Umjovo uyinto emhlophe, evulekile noma i-amorphous solid.I-Bivarudine ingakwazi ukubopha ngokuqondile indawo ye-thrombin catalytic kanye ne-anion yangaphandle yokubopha isayithi, futhi ivimbele ngokuqondile umsebenzi we-thrombin, ngaleyo ndlela ivimbele ukusabela okubangelwa futhi okubangelwa i-thrombin, futhi umphumela wayo uyahlehla.I-Bivarudine isetshenziswa ngokuyinhloko njenge-anticoagulant ye-elective percutaneous coronary intervention (PCI) kubantu abadala.
I-Bivarudine iyi-inhibitor eqondile ye-thrombin, ebophezela ngokuqondile kumasayithi e-catalytic kanye ne-anion exo-binding sites of thrombin free kanye ne-thrombus.Inqubo yokubopha phakathi kwe-bivaludine ne-thrombin iyabuyiseleka emuva, futhi i-thrombin ingabuyisela umsebenzi wasekuqaleni webhayoloji we-thrombin ngokuthi i-enzymolysis kancane ye-peptide bond phakathi kwe-bivaludine Arg3-Pro4.
Ucwaningo lwe-in vitro lubonise ukuthi i-bivarudine ayikwazi nje ukuvimbela i-thrombin yamahhala yangemuva, kodwa futhi ivimbele ukubopha kwe-thrombin ngamahlule egazi ngaphandle kokuphazanyiswa yizinto ezikhishwe ama-platelet.Ingandisa isikhathi se-prothrombin (APTT), isikhathi se-thrombin (TT), isikhathi se-prothrombin (PT) nesikhathi sokuhlangana esisebenzayo (ACT) esicushwe yi-plasma evamile.Kukhona ubudlelwano bomugqa nokugcwala kwe-bivarudine, kodwa ukuthi ngabe lokhu kuhlobana kukhona yini ekusetshenzisweni komtholampilo akucacile.
Kuye kwabikwa ezincwadini ukuthi i-pharmacokinetics yeziguli ezibhekene ne-percutaneous coronary angioplasty (PTCA) i-linear ngemuva kokuphathwa kwe-intravenous ye-bivarudine.Isiguli sanikezwa i-1 mg / kg nge-intravenously njengomthamo womthwalo, kulandelwa enye infusion ye-IV ye-2.5 mg / kg / hr ngamahora we-4, egxilile ku-12.3 ± 1.7 mg / ml ku-vivo.I-Bivarudine isuswa ku-plasma nge-renal hydrolysis kanye nokuwohloka kwe-protease.Ingxenye yempilo yeziguli ezinomsebenzi wezinso ojwayelekile icishe ibe yimizuzu engama-25, kanti isigamu sempilo yeziguli ezinokwehluleka kwe-renal okumaphakathi nokubi kuyanwetshwa.Cishe i-25% ye-bivarudine ingasuswa nge-dialysis futhi isuswe nge-hemodialysis.I-ACT kufanele iqashwe ezigulini ezinokukhubazeka kwezinso.Kumavolontiya anempilo, umphumela we-anticoagulant wabonwa ngokushesha ngemuva kokuphathwa kwe-bivarudine nge-intravenous, nge-PT, ACT kanye ne-APTT ende.Ihora elilodwa kuya kwamabili ngemva kokuhoxa, i-ACT ibuyele ezingeni langaphambi kokuphatha.

imikhiqizo ehlobene

Cbz-Phe-Arg-OH	I-Boc-L-Arg-OH.HCl
I-Arg-Tyr-Oet	I-Boc-L-Arg-OH.HCl.H2O
I-HL-Arg-OH	I-Boc-D-Arg-OH•HCl•H2O
I-HD-Arg-OH	I-Boc-Arg(Cbz)-OH
I-DL-Arg-OH	Fmoc-L-Arg-OH
I-L-Arg-Ome.2Hcl	I-Fmoc-D-Arg-OH
I-D-Arg-Ome.2HCl	I-Fmoc-L-Arg(NO2)-OH
I-L-Arg(Pbf)-OH	I-Fmoc-L-Arg(Pbf)-OH
I-D-Arg(NO2)-OH / N-NO2-D-Arg	I-Fmoc-HoArg(Pbf)-OH
I-HL-Arg(NO2)-OH	I-Fmoc-Arg(Tos)-OH
I-HL-Arg(Tos)-OH	I-Fmoc-D-Arg(Tos)-OH
I-L-Arg-NH2	I-Fmoc-D-Arg(Pbf)-OH
I-Boc-L-Arg-OH	Cbz-Arg-OH
I-Boc-D-Arg(Pbf)	Cbz-D-Arg-OH
I-Boc-Arg-Oet	Cbz-L-Arg(Pbf)-OH
Boc-L-Arg-Ome	Cbz-D-Arg(pbf).CHA
I-Boc-L-Arg(Tos)-OH	Cbz-D-Arg-Gly-OH
I-Boc-L-Arg(NO2)-OH	I-L-Arg(Pbf)-Asp
Fmoc-L-HomoArg-OH	L-Homoarg.hcl

Ukuphakama

1. Isevisi ye-R&D iyatholakala
2. Umkhiqizi oqinisekisiwe we-ISO, isiqinisekiso sekhwalithi
I-3.Inkambo ephelele yenkonzo yokulandelela ngesikhathi sokukhiqiza
I-4.Izindleko eziphezulu
5.Imibhalo yesitifiketi sekhwalithi enikeziwe ngokwesicelo sekhasimende ngalinye
I-6.Isevisi enhle emva kokuthengisa, ukugcina ubuhlobo obuseduze nekhasimende
7.Insiza egcwele yokusiza ukwehlisa izindleko zokuthumela
8.Isampula yamahhala enikelwe ukuhlola ikhwalithi ngaphambi kwanoma iyiphi inkokhelo
9.Isikhathi sokukhokha okuxoxiswana ngaso
10.Amakhasimende e-Assit abhekana nezindaba zaseShayina